title: ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
authors.forename: Landi
authors.initials: L
authors.lastname: Lombard
authors.forename: Larry
authors.initials: L
authors.lastname: Distiller
authors.forename: Julia
authors.initials: J
authors.lastname: Aalbers
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D018149:Glucose Intolerance / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000009:adverse effects / Q000627:therapeutic use*; D061214:Patient Safety; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine